复宏汉霖(02696.HK)：HLX37在晚期/转移性实体瘤患者中的临床试验申请获国家药监局批准

Core Viewpoint - The company, Junshi Biosciences (复宏汉霖), has received approval from the National Medical Products Administration (NMPA) for its IND application of HLX37, a dual-specific antibody injection targeting PD-L1 and VEGF, for use in patients with advanced/metastatic solid tumors [1] Group 1 - The IND application for HLX37 has been approved, marking a significant milestone for the company's research and development efforts [1] - HLX37 is a recombinant humanized dual-specific antibody that targets both PD-L1 and VEGF, indicating its potential in cancer treatment [1] - The approval allows the company to proceed with clinical trials, which could lead to further advancements in its oncology pipeline [1]